secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2022-10-18T23:59:59+00:00
Accession:  0001193125-22-264447
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion announces FDA IND clearance for BMF-219 in KRAS solid tumors; Phase I/Ib trial to begin
--------------------------------------------------------------------------------

- FDA cleared IND for BMF-219 to initiate Phase I/Ib trial (COVALENT-102) in KRAS-mutant NSCLC, CRC, and PDAC.
- BMF-219 is the first menin inhibitor to enter clinical trials for solid tumors.
- Preclinical data showed pan-KRAS activity across G12C, G12D, G12V, and G13D mutations.
- Company already has COVALENT-101 Phase I trial in blood cancers underway.
- KRAS mutations present in 25-35% of NSCLC, 35-45% of CRC, and ~90% of PDAC patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522264447/0001193125-22-264447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522264447/d403732d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-264447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer